The publication of evidence summaries; new medicines (ESNMs) is a new service offered by NICE to assist commissioners, budgets holders and groups such as Area Prescribing Committees in managing the introduction of selected new medicines (or new indications or formulations for existing medicines) not covered by the Technology Appraisal programme. The topics selected are medicines that have recently gone onto the UK market or medicines that may be marketed in the UK in the next 6 - 12 months.
NICE has kicked off this new series with “Fidaxomicin (Dificlir) for the treatment of Clostridium difficile infection”. ESNMs provide a summary of the published evidence for selected new medicines considered to be of significance for the NHS. The strengths and weaknesses of the relevant evidence are critically reviewed within the summaries, but the summaries do not constitute formal NICE Guidance.
Under the NHS Constitution patients have the right to expect that decisions made locally about the funding of medicines and treatments will be made rationally following a proper consideration of the evidence. In the absence of a technology appraisal from NICE, ESNMs should help to ensure consistency of access to evidence for decision-makers.